San Francisco-based UCSF Benioff Children’s Hospitals has become the first U.S. qualified treatment center contracted to administer Waskyra (etuvetidigene autotemcel) to eligible patients with Wiskott-Aldrich syndrome.
The designation makes Waskyra commercially available to eligible patients in the U.S., according to a Sept. 28 news release. More treatment centers are expected to be added in the coming months.
The FDA approved Waskyra in December 2025 as the first gene therapy to treat Wiskott-Aldrich syndrome. It is approved for patients 6 months and older who have a mutation in the WAS gene, for whom hematopoietic stem cell transplantation is appropriate and who do not have a suitable human leukocyte antigen-matched related stem cell donor.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
